Goldman Sachs’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,962,841
| Closed | -$30.9M | – | 6018 |
|
|
2024
Q1 | $30.9M | Sell |
1,962,841
-344,634
| -15% | -$5.3M | 0.01% | 1501 |
|
|
2023
Q4 | $37.2M | Buy |
2,307,475
+290,968
| +14% | +$3.71M | 0.01% | 1392 |
|
|
2023
Q3 | $25.6M | Sell |
2,016,507
-107,527
| -5% | -$1.48M | 0.01% | 1595 |
|
|
2023
Q2 | $29.9M | Sell |
2,124,034
-933,879
| -31% | -$13.4M | 0.01% | 1506 |
|
|
2023
Q1 | $47.2M | Buy |
3,057,913
+857,540
| +39% | +$14.3M | 0.01% | 1108 |
|
|
2022
Q4 | $36.1M | Sell |
2,200,373
-1,566,480
| -42% | -$25.5M | 0.01% | 1442 |
|
|
2022
Q3 | $69.7M | Buy |
3,766,853
+103,034
| +3% | +$1.62M | 0.02% | 875 |
|
|
2022
Q2 | $48.2M | Buy |
3,663,819
+2,861,642
| +357% | +$31.6M | 0.01% | 1147 |
|
|
2022
Q1 | $7.44M | Sell |
802,177
-2,833,333
| -78% | -$24.1M | ﹤0.01% | 2979 |
|
|
2021
Q4 | $35.5M | Buy |
3,635,510
+3,202,527
| +740% | +$60.2M | 0.01% | 1625 |
|
|
2021
Q3 | $14.7M | Buy |
432,983
+17,769
| +4% | +$567K | ﹤0.01% | 2360 |
|
|
2021
Q2 | $15.2M | Sell |
415,214
-205,327
| -33% | -$7.95M | ﹤0.01% | 2297 |
|
|
2021
Q1 | $27.8M | Buy |
620,541
+35,940
| +6% | +$1.67M | 0.01% | 1649 |
|
|
2020
Q4 | $33.4M | Buy |
584,601
+242,927
| +71% | +$14.4M | 0.01% | 1448 |
|
|
2020
Q3 | $17.5M | Sell |
341,674
-213,701
| -38% | -$10.5M | 0.01% | 1832 |
|
|
2020
Q2 | $33.2M | Buy |
555,375
+82,778
| +18% | +$4.43M | 0.01% | 1283 |
|
|
2020
Q1 | $19.5M | Buy |
472,597
+224,502
| +90% | +$12.5M | 0.01% | 1528 |
|
|
2019
Q4 | $15.4M | Buy |
248,095
+99,916
| +67% | +$4.75M | ﹤0.01% | 2076 |
|
|
2019
Q3 | $5.03M | Buy |
148,179
+114,306
| +337% | +$3.38M | ﹤0.01% | 2862 |
|
|
2019
Q2 | $764K | Sell |
33,873
-24,244
| -42% | -$567K | ﹤0.01% | 4162 |
|
|
2019
Q1 | $1.35M | Buy |
58,117
+16,999
| +41% | +$445K | ﹤0.01% | 3882 |
|
|
2018
Q4 | $863K | Buy |
41,118
+29,220
| +246% | +$718K | ﹤0.01% | 4051 |
|
|
2018
Q3 | $461K | Buy |
11,898
+6,599
| +125% | +$244K | ﹤0.01% | 4463 |
|
|
2018
Q2 | $209K | Sell |
5,299
-7,678
| -59% | -$226K | ﹤0.01% | 4975 |
|
|
2018
Q1 | $260K | Buy |
+12,977
| New | +$329K | ﹤0.01% | 4859 |
|
|
2017
Q4 | – | Sell |
-75,000
| Closed | -$1.42M | – | 6721 |
|
|
2017
Q3 | $1.42M | Buy |
+75,000
| New | +$1.37M | ﹤0.01% | 4276 |
|
Other funds holding DCPH
Goldman Sachs's DCPH Position: Q2 2024 in Review
Goldman Sachs sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,962,841 shares — an estimated $30.9M sold.
Goldman Sachs first reported a position in DCPH in Q3 2017 and held it in 26 quarters. The position peaked at $69.7M in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Goldman Sachs reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Goldman Sachs sold 1,962,841 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $30.9M.
- Goldman Sachs first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 26 quarters.
- Goldman Sachs's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $69.7M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.